Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with poor survival, and platinum-etoposide chemotherapy is indicated as the mainstay of treatment. In this study, we compared the efficacy and safety between the cisplatin plus etoposide (EP) and carboplatin plus etoposide (EC) regimens. | Jiang et al. BMC Cancer 2021 21 1308 https s12885-021-09034-6 RESEARCH Open Access Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer a pooled analysis Shiyu Jiang1 6 Liling Huang2 Hongnan Zhen3 Peijie Jin4 Jing Wang5 6 and Zhihuang Hu1 6 Abstract Background Extensive-stage small cell lung cancer ES-SCLC is an aggressive disease with poor survival and platinum-etoposide chemotherapy is indicated as the mainstay of treatment. In this study we compared the efficacy and safety between the cisplatin plus etoposide EP and carboplatin plus etoposide EC regimens. Methods A total of 1305 patients with previously untreated ES-SCLC were included in this study. Data from five trials were collected from the public database Project Data Sphere. Survival analysis and adverse events AEs analysis were conducted. Results Of the 1305 patients 800 received the EC regimen whereas 505 received the EP regimen as their front-line treatment. Overall the median progression-free survival PFS and the median overall survival OS were 172 and 289 days respectively. The EP and EC treatment groups did not have significantly different PFS or OS. After adjusting for age sex body mass index BMI and Eastern Cooperative Oncology Group ECOG performance status PS the EP regimen was independently associated with better PFS hazard ratio HR 95 CI p and OS HR 95 CI p among patients who were overweight and obese BMI 25 kg m2 . In the safety analysis patients who received the EC treatment experienced significantly more grade 3 AEs n 599 than those who received the EP treatment n 337 p . Furthermore the EC regimen was asso- ciated with a higher risk of grade 3 4 neutropaenia p thrombocytopaenia p 200 000 cases 1 2 . Despite concurrent 1 Department of Medical Oncology Fudan University Shanghai Cancer chemoradiation and the initial response to platinum- Center Institute
